

## Disclaimer

### Acute Care & Critical Care Case-Based Reviews

Acute Cardiovascular Disorders

Anthony J. Busti, MD, PharmD, MSc, FNLA, FAHA  
Erika Heffner, PharmD, MBA, BCPS



- High-Yield Med Reviews has no working relationship with BPS (Board of Pharmacy Specialities)
- This live webinar event is not endorsed or sponsored by BPS or anyone other than High-Yield Med Reviews
- This is not meant to be a commercial or sales pitch



## Introduction



Anthony Busti, MD, PharmD, MSc, FNLA, FAHA



Erika Heffner, PharmD, MBA, BCPS

## Agenda

- Cases 1-4
- ACEP Clinical Policy Review
- A special coupon code & giveaway opportunity
- Live Q&A



## Integrated Case-Reviews

- Case 1 -



## Case 1


- 27-year-old male comes in with acute onset of “chest discomfort” with palpitations. He also reports he has a sensation that it’s harder to breathe.
- This started about 30 minutes prior to arrival.
- He denies any PMH or allergies
- He denies any medication use (including OTC)
- The triage nurse checks him in and sends the patient back to the critical care room for a reported pulse of 210 beats per minute.




## Case 1

- VS:
  - Temp = 98.8, P = 200 bpm, BP = 135/89, RR = 22, O2Sat = 96% (RA)
- Differential Diagnosis:
  - Afib with RVR
  - Aflutter
  - PE
  - Cardiac tamponade
  - Tension pneumothorax
  - Toxic ingestion
  - \_\_\_\_\_
  - \_\_\_\_\_

## Case 1



## Case 1



## Case 1

- Plan:
  - IV placement (most proximal position)
  - Stop cock with 20 cc syringe of NS + IVF
  - Extend + \_\_\_\_\_ just above the level of heart
  - Crash cart set up → Continuous ECG
  - \_\_\_\_\_

## Case 1

| Core Principles of Pharmacokinetics |  |
|-------------------------------------|--|
| Absorption                          | Parenteral administration so → IV Push<br>F (bioavailability) = 100%             |
| Distribution                        | _____ → helps<br>distribute towards heart  |
| Metabolism                          | Rapid uptake by endothelial cells and<br>metabolism by adenosine kinase          |
| Elimination                         | Rapid metabolism → half-life = _____   |
| Core Principle of Pharmacodynamics  |  |
| Mechanism of Action                 | Slows nodal conduction leading to<br>bradycardia and/or short period of asystole |

## Case 1

- What happens if adenosine doesn't work?
  - Adenosine 12 mg x \_\_\_ dose(s)
  - What if that fails or if the patient decompensates?
    - “Synchronized cardioversion” vs. “Defibrillation”
    - Synchronized cardioversion at \_\_\_\_\_ → \_\_\_\_\_ joules
- What is the initial dose if you have a central line?
  - \_\_\_\_\_ IVP
- What about if the patient is a heart transplant?
  - \_\_\_\_\_ IVP

## Integrated Case-Reviews

- Case 2 -



## Case 2

- A 54-year-old female with a PMH of DM2, HTN, HFrEF, chronic low-back pain comes in by EMS with reports of waking up this morning with a sudden onset of shortness of breath.
- She denies any chest pain or pressure, N/V, cough, but indicates she has had worsening bilateral LE swelling.
- EMS reports her BP in route was 213/106 mmHg and a pulse of 105 bpm. She is on supplemental O2 at 5 liters per min.




## Case 2

- VS:
  - P = 110 bpm, BP = 210/105 mmHg, RR = 24, O2 sat on RA is 86% → 93% on 4 L per NC
- Exam:
  - Awake, but visible in respiratory distress, Bilateral crackles on lung exam, 2+ Bilateral LE edema cool to touch
- Differential Diagnosis:
  - \_\_\_\_\_
  - NSTEMI or STEMI
  - Pneumothorax
  - PE
  - Pneumonia



## Case 2

Chest Radiograph (AP)



Bedside US (\_\_\_\_\_)




Imaging is done for 3 reasons:

1. Add to the \_\_\_\_\_ findings
2. Help determine \_\_\_\_\_
3. Rule out pneumothorax if \_\_\_\_\_ are to be used



## Case 2



## Case 2

- Treatment Plan
  - NPPV (CPAP or BiPAP)
    - Can this also make the patient worse?
  - Vasodilators
    - \_\_\_\_\_ (Dose and Route): Does it matter?
  - Diuretic therapy
    - Drug, dose, route?
    - Does the rate of administration matter?
    - Evidence: Does the TRANSFORM-HF Trial change anything?



## Case 2

- What if the patient was hypotensive?
  - What impact does that have on NPPV, vasodilators, and diuretics
  - Inotrope of choice?
    - \_\_\_\_\_ → but ....
    - +/- Vasopressor → drug of choice?
      - \_\_\_\_\_



## ACEP Clinical Policy Statements

- In adult patients presenting to the ER with suspected acute HF, is the diagnostic accuracy of point-of-care lung ultrasound sufficient to direct clinical management?
  - Level A Recommendations: None.
  - Level B Recommendations
    - **Use point-of-care lung ultrasound** as an imaging modality in conjunction with medical history and physical examination to diagnose acute heart failure syndrome **when diagnostic uncertainty exists**, as the accuracy of this diagnostic test is sufficient to direct clinical management.\*
      - \* Use of lung ultrasound requires that the equipment is available, and the physician is proficient in its use.
  - Level C Recommendations: None.



## ACEP Clinical Policy Statements

- In adult patients presenting to the ER with suspected acute HF, is vasodilator therapy with high-dose \_\_\_\_\_ administration safe and effective?
  - Level A Recommendations: None
  - Level B Recommendations: None
  - Level C Recommendations
    - Consider **using \_\_\_\_\_ as a safe and effective treatment option when administered to patients with acute heart failure syndrome and elevated blood pressure** (Consensus recommendation).\*
      - \* Although \_\_\_\_\_ infusions of up to \_\_\_\_\_ mcg/min have been described as "standard dosing," some may consider a dosage of \_\_\_\_\_ mcg/min or higher as "high dose." "High dose" \_\_\_\_\_ has also been described as bolus intravenous dosing of 2,000 mcg every 3 to 5 minutes.



## Integrated Case-Reviews

- What Does ACEP Recommend? -



## ACEP Clinical Policy Statements

- In adult patients presenting to the ER with suspected acute HF, is early administration of diuretics safe and effective?
  - Level A Recommendations: None
  - Level B Recommendations: None
  - Level C Recommendations
    - Although **no specific timing of diuretic therapy can be recommended**, physicians may consider earlier administration of diuretics when indicated for emergency department patients with acute heart failure syndrome, because it may be associated with reduced length of stay and in-hospital mortality (Consensus recommendation).
    - Physicians should be confident in the diagnosis of acute heart failure syndrome with volume overload in a patient before the administration of diuretics because treatment with diuretics may cause harm to those with an alternative diagnosis (Consensus recommendation).



## ACEP Clinical Policy Statements

- In adult patients presenting to the ER with symptomatic acute HF, is there a defined group that may be safely discharged home for outpatient follow-up?
  - Level A Recommendations: None
  - Level B Recommendations
    - Do not rely on current acute heart failure syndrome risk stratification tools alone to determine which patients may be discharged directly home from the emergency department.
    - **Consider using the Ottawa Heart Failure Risk Scale (OHFRS) to help determine which higher-risk patients for adverse outcome should not be discharged home.**
  - Level C Recommendations
    - Consider using the **Emergency Heart Failure Mortality Risk Grade for 7-day mortality (EHMRG7)** or the **STRATIFY decision tool** to help determine which higher-risk patients for adverse outcome should not be discharged home.
    - Use shared decision-making strategies when determining the appropriate disposition of AHFS patients (Consensus recommendation).



# Integrated Case-Reviews

- Case 3 -




## Case 3

- A 48-year-old male with a PMH of HFpEF, HTN, gout, and depression comes in with worsening SOB and palpitations and is found to be in AFib with RVR.
- VS:
  - P = 152 bpm, BP = 149/89
- Exam:
  - Awake and alert
  - Irregularly irregular pulse
  - Unremarkable lung exam
  - 1+ bilateral LE edema




## Case 3




- Why is the rate in RVR commonly around 150?
- What else do we need to worry about before jumping to treatment?



## Case 3



- AFIB \_\_\_\_\_
- 1. Rates > \_\_\_\_\_
- 2. Wider QRS with some beat-to-beat variability



## Case 3

- Treatment Plan:
  - Rate or rhythm control with which agent?
    - Diltiazem vs. Beta-blockers vs. Digoxin vs Antiarrhythmic
    - Evidence: \_\_\_\_\_ Trial → rate control > rhythm control which had trends to worse outcomes
  - What if the patient has WPW?
    - \_\_\_\_\_
  - To what goal pulse?
    - \_\_\_\_\_ Trial
    - Pulse < \_\_\_\_\_ bpm = < \_\_\_\_\_ bpm in preventing CV events
  - Other considerations:
    - Fluid overload, electrolyte abnormalities, thyroid disorders



# Integrated Case-Reviews

- Case 4 -




## Case 4

- A 45-year-old male with a well-known history of cocaine abuse and uncontrolled hypertension due to medication non-compliance comes in complaining of sudden onset of severe chest pain radiating to the back between his shoulder blades.
- Upon walking into the room, the patient is sweating, visibly uncomfortable, and has the following VS:
  - P = 110, BP = 225/112



## Case 4



## Case 4

- Who is at risk:
  - Hx of HTN and cocaine use
  - Connective tissue disorders (Marfan, Ehlers-Danlos Syndromes)
  - Bicuspid aortic valves
- Approaches to Treatment
  - Consult CVT surgery
  - Control the pain → reduces sympathetic tone
  - Get pulse and BP under control (especially Type A)
    - Classic teaching = P < \_\_\_\_\_ bpm and SBP < \_\_\_\_\_ mmHg
    - Treatments:
      - Rate Control: Beta-blockers: Esmolol or labetalol
      - Afterload Reductions: +/- nicardipine or clevidipine or nitroprusside



## ACEP Clinical Policy Statements

- Are there any decision tools to identify those with low-risk for diagnosis of aortic dissection (AD)?
  - \_\_\_\_\_
- Can D-dimer be used to identify low-risk patients?
  - \_\_\_\_\_
- What imaging is best?
  - CTA = TEE = MRA
- Does a target heart rate or BP lowering reduce mortality or morbidity?
  - \_\_\_\_\_ targets but both pulse and SBP should be treated



## ACEP Clinical Policies

- Acute VTE -



## ACEP Clinical Policy Statements

- Can a clinical prediction rule be used to identify a group of patients at very low risk for the diagnosis of PE for whom no additional diagnostic workup is required?
  - Level B: Yes; the \_\_\_\_\_ rule
- Does a negative age-adjusted D-dimer result identify a group of patients at very low risk for the diagnosis of PE for whom no additional diagnostic workup is required?
  - Level B: In patients older than 50 years deemed to be low or intermediate risk for acute PE, clinicians may use a negative age-adjusted D-dimer\* result to exclude the diagnosis of PE.
    - \*For highly sensitive D-dimer assays using fibrin equivalent units (FEU) use a cutoff of age×10 µg/L; for highly sensitive D-dimer assays using D-dimer units (DDU), use a cutoff of age×5 µg/L.
- In adult patients with subsegmental pulmonary embolism (PE), is it safe to withhold anticoagulation?
  - Given the lack of evidence, anticoagulation treatment decisions for patients with subsegmental PE without associated deep venous thrombosis (DVT) should be guided by individual patient risk profiles and preferences. [Consensus recommendation]

## ACEP Clinical Policies

- NSTEMI-



## ACEP Clinical Policy Statements

- Should patients with \_\_\_\_\_ receive immediate antiplatelet therapy in addition to aspirin to reduce 30-day major adverse cardiac events?
  - Level C: \_\_\_\_\_ and glycoprotein IIb/IIIa inhibitors **may** be given in the emergency department **or delayed** until cardiac catheterization

## ACEP Clinical Policy Statements

- In adult patients diagnosed with acute pulmonary embolism (PE), is the initiation of anticoagulation and discharge from the emergency department (ED) safe?
  - Level C: Selected patients with acute PE who are at low risk for adverse outcomes as determined by **Pulmonary Embolism Severity Index (PESI), simplified PESI (sPESI), or the Hestia criteria may be safely discharged from the ED on anticoagulation**, with close outpatient follow-up.
- Is treatment with a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) safe and effective compared with treatment with low-molecular-weight heparin (LMWH) and vitamin K antagonist (VKA)?
  - Level B: In selected patients diagnosed with acute DVT, a NOAC may be used as a safe and effective treatment alternative to LMWH/VKA.
  - Level C: Selected patients with acute DVT may be safely treated with a NOAC and directly discharged from the ED.

## ACEP Clinical Policy Statements

- In adult patients without evidence of STEMI, can initial risk stratification be used to predict a low rate of 30-day major adverse cardiac events?
  - Level B: Yes; The History, ECG, Age, Risk factors, Troponin (\_\_\_\_\_) score can be used as a clinical prediction instrument for risk stratification.
    - A low score (≤ \_\_\_) predicts a 30-day major adverse cardiac event miss rate within a range of 0% to 2%
- In adults ruled out for NSTEMI and low-risk, when should patients follow up?
  - Level C: 1-2 weeks
    - If \_\_\_\_\_ available; but if not, then obs admission

## ACEP Clinical Policies

- Reperfusion Therapy for STEMI-



## ACEP Clinical Policy Statements

- In STEMI, are there patients for whom treatment with fibrinolytic therapy decreases the incidence of MACE when PCI is delayed?
  - Level B: Fibrinolytics may be administered to patients when door-to-balloon (D2B) time is anticipated to \_\_\_\_\_.
  - Level C: A dose reduction \_\_\_\_\_ considered when administering fibrinolytics to patients aged 75 years or older.
- In STEMI, does transfer to a PCI center decrease the incidence of MACE?
  - Level B: Yes, patients with STEMI should be transferred to a PCI-capable hospital as soon as possible.

## ACEP Clinical Policy Statements

- In adult patients undergoing reperfusion therapy, should \_\_\_\_\_ be avoided to prevent adverse outcomes?
  - Level C: Because safety has not been established, clinical judgment should be used in deciding whether to provide or withhold \_\_\_\_\_ in patients undergoing reperfusion therapy.
  - But, what about \_\_\_\_\_?

## Coupon & Feedback

- Limited time coupon
  - Coupon = \_\_\_\_\_
    - 10% OFF ENTIRE ORDER
  - Expires = **February 28, 2023**
- We value your feedback.
  - Only 2 minutes of your time on this free webinar event and enter a chance to win \$100 gift card.
  - <https://high-yield-webinar-survey.paperform.co/>



## Live Q&A



**HIGH-YIELD  
MED REVIEWS**